Assessment of the Level of Matrix Metalloproteinases, VEGF and MicroRNA-34a in Patients With Non-obstructive and Obstructive Lesions of the Coronary Arteries

Aim. To assess the levels of matrix metalloproteinases (MMP), vascular endothelial growth factor (VEGF), and miRNA-34a expression in patients with ischemic heart disease (IHD) and obstructive and nonobstructive coronary artery (CA) disease.

Material and methods. This cross-sectional observational study included 64 patients with IHD (diagnosis verified by coronary angiography or multislice computed tomography coronary angiography), of which 33 (51.6%) were men aged 64.9±8.1 years. 20 patients had nonobstructive CA disease (stenosis <50%), and 44 had hemodynamically significant stenoses. The control group consisted of 30 healthy volunteers. MMP-1, -9, -13, and -14, miRNA-34a, and VEGF were measured in all patients.

Results. The concentration of MMP-1 was significantly higher in patients with ischemia and nonobstructive CA disease (INOCAD) (p=0.016), and the concentration of MMP-9 was the highest in the group with obstructive CA disease (p<0.001). The concentrations of MMP-13 and MMP-14 did not differ significantly between the groups. The highest VEGF concentrations were observed in the INOCAD group (p<0.001). The expression of miRNA-34a significantly differed between the IHD groups with different types of CA disease and controls (p <0.001). Patients with hemodynamically significant stenosis showed moderate relationships between the concentrations of MMP-14 and VEGF (ρ=0.418; p=0.024), as well as between VEGF and miRNA-34a (ρ=0.425; p=0.022). Patients with INOCAD had a significant negative correlation between the concentrations of MMP-13 and VEGF (ρ= –0.659; p=0.003). Correlation analysis showed in all IHD patients a moderate relationship of the concentrations of MMP-1 and MMP-14 with VEGF (ρ=0.449; p=0.002 and p=0.341; p=0.019, respectively). According to ROC analysis, a MMP-9 concentration above 4.83 ng/ml can be a predictor for the presence of hemodynamically significant CA obstruction in IHD patients; a VEGF concentration higher than 27.23 pg/ml suggests the absence of hemodynamically significant CA stenosis.

Conclusion. IHD patients with INOCAD had the greatest increase in MMP-1, whereas patients with obstructive CA disease had the highest level of MMP-9. According to our data, concentrations of MMP-9 and VEGF can be used to predict the degree of CA obstruction. The expression of miRNA-34a was significantly higher in IHD patients with INOCAD and CA obstruction than in the control group, which suggested a miRNA-34a contribution to the development and progression of coronary atherosclerosis. In the future, it may be possible to use this miRNA as a diagnostic marker for IHD.

1. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL et al. Heart Disease and Stroke Statistics–2023 Update: A Report From the American Heart Association. Circulation. 2023;147(8):e93–621. DOI: 10.1161/CIR.0000000000001123

2. Mangge H, Almer G. Immune-Mediated Inflammation in Vulnerable Atherosclerotic Plaques. Molecules. 2019;24(17):3072. DOI: 10.3390/molecules24173072

3. Myasoedova VA, Chistiakov DA, Grechko AV, Orekhov AN. Matrix metalloproteinases in pro-atherosclerotic arterial remodeling. Journal of Molecular and Cellular Cardiology. 2018;123:159–67. DOI: 10.1016/j.yjmcc.2018.08.026

4. Nam S, Yu G, Kim H, Park K, Chung J, Ha E et al. A polymorphism at –1607 2G in the matrix metalloproteinase-1 (MMP-1) increased risk of sudden deafness in korean population but not at –519A/G in MMP-1. The Laryngoscope. 2011;121(1):171–5. DOI: 10.1002/lary.21334

5. Olejarz W, Łacheta D, Kubiak-Tomaszewska G. Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability. International Journal of Molecular Sciences. 2020;21(11):3946. DOI: 10.3390/ijms21113946

6. Kowara M, Cudnoch-Jedrzejewska A, Opolski G, Wlodarski P. Micro RNA regulation of extracellular matrix components in the process of atherosclerotic plaque destabilization. Clinical and Experimental Pharmacology and Physiology. 2017;44(7):711–8. DOI: 10.1111/1440-1681.12772

7. Barbarash O.L., Karpov Yu.A., Kashtalap V.V., Boshchenko A.A., Ruda M.Ya., Akchurin R.S. et al. 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):201–50. DOI: 10.15829/1560-4071-2020-4076

8. Wu Y-W, Kao H-L, Chen M-F, Lee B-C, Tseng W-YI, Jeng J-S et al. Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. Journal of Nuclear Medicine. 2007;48(2):227–33. PMID: 17268019

9. Hwang J-J, Yang W-S, Chiang F-T, Chen M-F, Lin H-J, Huang P-J et al. Association of circulating matrix metalloproteinase-1, but not adiponectin, with advanced coronary artery disease. Atherosclerosis. 2009;204(1):293–7. DOI: 10.1016/j.atherosclerosis.2008.08.019

10. Kato R, Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F. Plasma Matrix Metalloproteinase-8 Concentrations are Associated With the Presence and Severity of Coronary Artery Disease. Circulation Journal. 2005;69(9):1035–40. DOI: 10.1253/circj.69.1035

11. Inoue T, Kato T, Takayanagi K, Uchida T, Yaguchi I, Kamishirado H et al. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome. The American Journal of Cardiology. 2003;92(12):1461–4. DOI: 10.1016/j.amjcard.2003.08.061

12. Lehrke M, Greif M, Broedl UC, Lebherz C, Laubender RP, Becker A et al. MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovascular Diabetology. 2009;8(1):50. DOI: 10.1186/1475-2840-8-50

13. Leber AW, Knez A, White CW, Becker A, Von Ziegler F, Muehling O et al. Composition of coronary atherosclerotic plaques in patients with acute myocardial infarction and stable angina pectoris determined by contrast-enhanced multislice computed tomography. The American Journal of Cardiology. 2003;91(6):714–8. DOI: 10.1016/S0002-9149(02)03411-2

14. Feuchtner G, Postel T, Weidinger F, Frick M, Alber H, Dichtl W et al. Is There a Relation between Non-Calcifying Coronary Plaques and Acute Coronary Syndromes? A Retrospective Study Using Multislice Computed Tomography. Cardiology. 2008;110(4):241–8. DOI: 10.1159/000112407

15. Henneman MM, Schuijf JD, Pundziute G, Van Werkhoven JM, Van Der Wall EE, Jukema JW et al. Noninvasive Evaluation With Multislice Computed Tomography in Suspected Acute Coronary Syndrome: Plaque Morphology on Multislice Computed Tomography Versus Coronary Calcium Score. Journal of the American College of Cardiology. 2008;52(3):216–22. DOI: 10.1016/j.jacc.2008.04.012

16. Qiang B, Toma J, Fujii H, Osherov AB, Nili N, Sparkes JD et al. Statin therapy prevents expansive remodeling in venous bypass grafts. Atherosclerosis. 2012;223(1):106–13. DOI: 10.1016/j.atherosclerosis.2012.03.013

17. Ezhov M, Safarova M, Afanasieva O, Mitroshkin M, Matchin Y, Pokrovsky S. Matrix Metalloproteinase 9 as a Predictor of Coronary Atherosclerotic Plaque Instability in Stable Coronary Heart Disease Patients with Elevated Lipoprotein(a) Levels. Biomolecules. 2019;9(4):129. DOI: 10.3390/biom9040129

18. Lahdentausta L, Leskelä J, Winkelmann A, Tervahartiala T, Sorsa T, Pesonen E et al. Serum MMP-9 Diagnostics, Prognostics, and Activation in Acute Coronary Syndrome and Its Recurrence. Journal of Cardiovascular Translational Research. 2018;11(3):210–20. DOI: 10.1007/s12265-018-9789-x

19. Koenig W, Khuseyinova N. Biomarkers of Atherosclerotic Plaque Instability and Rupture. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27(1):15–26. DOI: 10.1161/01.ATV.0000251503.35795.4f

20. Mattson M, Wan R. Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems. The Journal of Nutritional Biochemistry. 2005;16(3):129–37. DOI: 10.1016/j.jnutbio.2004.12.007

21. Eaton CB, Gramling R, Parker DR, Roberts MB, Lu B, Ridker PM. Prospective association of vascular endothelial growth factor-A (VEGF-A) with coronary heart disease mortality in Southeastern New England. Atherosclerosis. 2008;200(1):221–7. DOI: 10.1016/j.atherosclerosis.2007.12.027

22. Bonanni A, d’Aiello A, Pedicino D, Di Sario M, Vinci R, Ponzo M et al. Molecular Hallmarks of Ischemia with Non-Obstructive Coronary Arteries: The “INOCA versus Obstructive CCS” Challenge. Journal of Clinical Medicine. 2022;11(6):1711. DOI: 10.3390/jcm11061711

23. Mirhafez SR, Zarifian A, Ebrahimi M, Ali RFA, Avan A, Tajfard M et al. Relationship between serum cytokine and growth factor concentrations and coronary artery disease. Clinical Biochemistry. 2015;48(9):575–80. DOI: 10.1016/j.clinbiochem.2015.02.002

24. Tabuchi T, Satoh M, Itoh T, Nakamura M. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clinical Science. 2012;123(3):161–71. DOI: 10.1042/CS20110563

25. Han H, Qu G, Han C, Wang Y, Sun T, Li F et al. MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32 patient cohort. Experimental & Molecular Medicine. 2015;47(2):e138. DOI: 10.1038/emm.2014.81

26. Badi I, Mancinelli L, Polizzotto A, Ferri D, Zeni F, Burba I et al. miR-34a Promotes Vascular Smooth Muscle Cell Calcification by Downregulating SIRT1 (Sirtuin 1) and Axl (AXL Receptor Tyrosine Kinase). Arteriosclerosis, Thrombosis, and Vascular Biology. 2018;38(9):2079–90. DOI: 10.1161/ATVBAHA.118.311298

27. Zuccolo E, Badi I, Scavello F, Gambuzza I, Mancinelli L, Macrì F et al. The microRNA-34a-Induced Senescence-Associated Secretory Phenotype (SASP) Favors Vascular Smooth Muscle Cells Calcification. International Journal of Molecular Sciences. 2020;21(12):4454. DOI: 10.3390/ijms21124454

28. Kim JS, Pak K, Goh TS, Jeong DC, Han M-E, Kim J et al. Prognostic Value of MicroRNAs in Coronary Artery Diseases: A Meta-Analysis. Yonsei Medical Journal. 2018;59(4):495. DOI: 10.3349/ymj.2018.59.4.495

29. Pufe T, Harde V, Petersen W, Goldring MB, Tillmann B, Mentlein R. Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. The Journal of Pathology. 2004;202(3):367–74. DOI: 10.1002/path.1527

30. Vašků A, Meluzín J, Blahák J, Kincl V, Pávková Goldbergová M, Sitar J et al. Matrix Metalloproteinase 13 Genotype in rs640198 Polymorphism Is Associated with Severe Coronary Artery Disease. Disease Markers. 2012;33(1):43–9. DOI: 10.1155/2012/795739

31. Basu P, Sen U, Tyagi N, Tyagi SC. Blood flow interplays with elastin: collagen and MMP: TIMP ratios to maintain healthy vascular structure and function. Vascular Health and Risk Management. 2010;6:215–28. DOI: 10.2147/VHRM.S9472

32. Holm PW, Slart RHJA, Zeebregts CJ, Hillebrands JL, Tio RA. Atherosclerotic plaque development and instability: A dual role for VEGF. Annals of Medicine. 2009;41(4):257–64. DOI: 10.1080/07853890802516507

33. Alieva A.M., Reznik E.V., Teplova N.V., Melikulov A.A., Akhmedova M.F., Kotikova I.A. et al. MicroRNA-34a in cardiovascular disease: a glimpse into the future. Russian Cardiology Bulletin. 2023;18(1):14–22. DOI: 10.17116/Cardiobulletin20231801114

34. Ghafouri-Fard S, Abak A, Talebi SF, Shoorei H, Branicki W, Taheri M et al. Role of miRNA and lncRNAs in organ fibrosis and aging. Biomedicine & Pharmacotherapy. 2021;143:112132. DOI: 10.1016/j.biopha.2021.112132

35. Liu XQ, Mao Y, Wang B, Lu XT, Bai WW, Sun YY et al. Specific Matrix Metalloproteinases Play Different Roles in Intraplaque Angiogenesis and Plaque Instability in Rabbits. PLoS ONE. 2014;9(9):e107851. DOI: 10.1371/journal.pone.0107851

36. Tanindi A. Relationship Between MMP-1, MMP-9, TIMP-1, IL-6 and Risk Factors, Clinical Presentation, Extent and Severity of Atherosclerotic Coronary Artery Disease. The Open Cardiovascular Medicine Journal. 2011;5(1):110–6. DOI: 10.2174/1874192401105010110

37. Caselli C, Di Giorgi N, Ragusa R, Lorenzoni V, Smit J, El Mahdiui M et al. Association of MMP9 with adverse features of plaque progression and residual inflammatory risk in patients with chronic coronary syndrome (CCS). Vascular Pharmacology. 2022;146:107098. DOI: 10.1016/j.vph.2022.107098